NEWS CENTER

Position:

Group Announcement

Media reports

Group News

The 10th Session, 3rd Meeting of the Employee Congress (Members’ Congress) of Shijiazhuang Fourth Pharmaceutical and the Group’s 2022 Advanced Commendation Conference were solemnly held.

Category:

Group News

Party building and trade union

Time：2023-03-25

As spring returns to the earth and all things are renewed, the 10th Session’s Third Congress of the Employee Representatives and Members’ Congress, along with the Group’s 2022 Advanced Workers’ Commendation Conference, was solemnly held on the morning of March 25 at Shijiazhuang Fourth Pharmaceutical. The members of the Presidium—Qu Jiguang, Su Xuejun, Wu Hengyao, Han Shuqin, Shi Jianhui, Meng Guo, Sun Lijie, Song Mingxia, and Wang Jie—sat at the presiding platform, joined by employee representatives, member representatives, and outstanding workers and producers from various workshops and departments across the Group. Together, they discussed development strategies, deliberated on major plans, and jointly drew up a blueprint for the Group’s innovative, green, and high-quality development. The conference was chaired by Wu Hengyao, President of the Group.

The 10th Session, 3rd Meeting of the Employee Congress (Members’ Congress) of Shijiazhuang Fourth Pharmaceutical and the Group’s 2022 Advanced Commendation Conference were solemnly held.

Spring has returned to the earth, bringing renewal and vitality to all things. On the morning of March 25, Shijiazhuang Fourth Pharmaceutical’s 10th Session’s Third Congress of Employee Representatives and Members’ Congress, together with the Group’s 2022 Advanced Workers’ Commendation Ceremony, was solemnly held. The members of the Presidium—Qu Jiguang, Su Xuejun, Wu Hengyao, Han Shuqin, Shi Jianhui, Meng Guo, Sun Lijie, Song Mingxia, and Wang Jie—sat at the presiding platform, joined by employee representatives, member representatives, and outstanding workers and producers from various workshops and departments across the Group. Together, they discussed development strategies, deliberated on major plans, and jointly drew up a blueprint for the Group’s innovative, green, and high-quality development. The Group’s President, Wu Hengyao, presided over the congress.

At 8:20 a.m., the conference opened amid the solemn and majestic sound of the national anthem.

At the Group’s 2022 Advanced Commendation Conference, Shi Jianhui, Secretary of the Group’s Party Committee, and Han Shuqin, Executive President, respectively read out the “Decision on Commending Advanced Collectives and Individuals for 2022” and the “Decision on Commending Advanced Collectives and Individuals for Promoting Production and Ensuring Supply in 2022.” The advanced collectives and individuals who demonstrated outstanding performance in the Group’s production and business operations in 2022 and made remarkable contributions to promoting production and ensuring supply in 2022 were publicly recognized and commended. Amidst cheerful music and enthusiastic applause, representatives of the advanced collectives and individuals took to the stage and received medals and certificates bearing their well-deserved honors from the hands of the Group’s leaders.

Liu Yuqiang, an outstanding worker from the Second Division of Active Pharmaceutical Ingredients at the R&D Center, delivered a speech on behalf of the honored advanced collectives and individuals. He stated that they would cherish this honor, continue their efforts with renewed vigor, carry forward the spirit of model workers, the spirit of labor, and the spirit of craftsmanship, integrate their personal aspirations into the broader development of the Group’s business, and achieve even greater victories and glory through innovative achievements. They will strive to demonstrate new responsibilities and attain new accomplishments in the new journey of promoting the Group’s innovative, green, and high-quality development!

At the 3rd Session of the 10th Congress of Members of Shijiazhuang Fourth Pharmaceutical, the congress successively adopted by vote the bylaws for the by-election of committee members, the election procedures for the chairman and vice-chairmen, as well as the list of poll watchers and vote counters. The congress conducted a secret ballot to fill the vacancies on the 10th-term Trade Union Committee and elected the chairman and vice-chairmen of the Shijiazhuang Fourth Pharmaceutical Trade Union. Chen Jing and Liu Jing were elected as new members of the Shijiazhuang Fourth Pharmaceutical Trade Union Committee. Huang Xiaofeng was elected as the chairman of the Shijiazhuang Fourth Pharmaceutical Trade Union, while Chen Jing and Liu Jing were appointed as vice-chairmen.

The newly elected union chairman, Huang Xiaofeng, delivered a statement. He said that in his future work, he would take the Trade Union Law and the union’s articles of association as guiding principles, wholeheartedly serve union members and employees, and consciously accept the leadership of the Group Party Committee and higher-level trade unions. With the strong support of the Group’s Board of Directors and the management team, he pledged to closely focus on the central task of accelerating the Group’s innovative, green, and high-quality development, unite and lead all union members and employees, fulfill their duties conscientiously, work diligently, and willingly submit to supervision—thus living up to their mission and making a valuable contribution to building the Group into a first-class pharmaceutical enterprise in China and propelling the Group’s high-quality development in the new era to a new level!

Striving hard paves the way for brilliance; practical action writes a new chapter. The 161 employee representatives, entrusted with the heavy expectations of their colleagues, attended the Third Session of the 10th Employee Congress of Shijiazhuang No.4 Pharmaceutical Co., Ltd., fulfilling their glorious mission of democratic participation in enterprise management.

At the meeting, entrusted by the Group’s Board of Directors and leadership team, Chairman Su Xuejun delivered the “Group Business Performance Report.” The report systematically reviewed the Group’s performance in 2022 against its key business indicators, as well as the achievements made in areas such as product operations, new product R&D, technological transformation project construction, quality assurance, capital management, and employee welfare. The report also laid out plans and arrangements for the Group’s business indicators and key operational tasks in 2023: First, we must coordinate efforts to enhance the quality and efficiency of finished dosage form sales, concentrating our resources on expanding and optimizing the markets for oral solid dosage forms and aqueous injections, accelerating the optimization and upgrading of the production and sales structure, and continuously increasing the market share of new products; second, we should actively foster a new pattern of coordinated and competitive development of bulk and specialty APIs in both domestic and international markets, achieving a balance between production and sales; third, we must unswervingly pursue the path of “combination of generic and innovative drug development,” striving for new breakthroughs in accelerating the development of specialty generics, high-end complex formulations, and innovative drugs; fourth, we must comprehensively advance ongoing and newly initiated projects, creating new engines and opening up new space for the Group to speed up its transformation and upgrading and achieve leaps and bounds; fifth, we must strengthen the Group’s fundamental management, ensuring the safe and stable development of the enterprise and continuously improving the level of quality control and production safety throughout the entire process; sixth, we must keep enhancing employees’ sense of happiness, fulfillment, and belonging, appropriately raising their benefits and remuneration while ensuring continued growth in labor productivity and corporate economic efficiency.

The conference also heard the report delivered by Zhang Sumei, Deputy General Manager of the Group’s Strategic Development and Human Resources Center, on the Group’s 2023 annual economic responsibility system and employee salary adjustment measures.

During the breakout sessions, employee representatives carefully reviewed and discussed documents such as Su Xuejun’s “Report on the Group’s Business Operations.” They actively offered insightful suggestions and proposals, many of which provided valuable lessons and references for the company’s sustained and healthy development. This fully demonstrated the employee representatives’ sense of ownership and dedication to the company’s success, as well as their high expectations for the enterprise’s future growth. Group leaders responded on-site, addressing one by one the opinions and suggestions raised by the attending employee representatives.

By a show of hands, all employee representatives unanimously approved the “Group Business Operation Report” presented by Su Xuejun and the “Report on the Group’s 2023 Economic Responsibility System and Employee Salary Adjustments” presented by Zhang Sumei.

Amid warm applause, Qu Jiguang, Chairman of the Group’s Board of Directors, delivered a concluding speech. He pointed out that 2023 marks the inaugural year for fully implementing the spirit of the 20th National Congress of the Communist Party of China; it is a pivotal year—serving as both a bridge and a foundation for carrying forward the Group’s 14th Five-Year Plan and laying the groundwork for its high-quality development. With the new COVID-19 prevention and control policies taking effect and the series of reform measures just adopted at the Two Sessions, the market is now poised for a steady recovery, and these developments have opened up new opportunities for the comprehensive revitalization of the pharmaceutical industry. He emphasized that we must closely focus on the Group’s business objectives for 2023, seize market development opportunities, vigorously implement the “Go Out, Invite In” strategy, and continuously boost economic vitality. We must also pursue an innovation-driven strategy, strengthen original and leading-edge technological research, promote deep integration among the innovation chain, industrial chain, capital chain, and talent chain, and coordinate both qualitative improvements and quantitative growth in R&D projects, continually building up innovative momentum. We need to accelerate the implementation of ongoing projects, spare no effort to ensure that all engineering projects are completed, put into operation, and yield results as early as possible, thereby continuously empowering enterprises and giving them a strong head start. Finally, we must rely on our employees to run the enterprise, deepen reforms in the construction of the industrial workforce, enable skilled professionals to stand out, and enable them to achieve remarkable success on this new journey.

Qu Jiguang emphasized that, in the face of daunting development tasks, everyone throughout the group must continue to maintain strategic composure, vigorously promote investigation and research, build consensus on development, remain firmly confident, take responsibility, forge ahead with vigor, work diligently and down-to-earth, and unite and lead all employees to strive tirelessly toward building a first-class pharmaceutical enterprise in China and fully advancing the group’s innovative, green, and high-quality development!

Unity unites strength; struggle creates the future. The conference calls upon all employees to deeply study and implement the spirit of the 20th National Congress of the Communist Party of China, vigorously promote the spirit of model workers, the spirit of labor, and the spirit of craftsmanship, and consciously integrate personal aspirations into the powerful tide of enterprise innovation and high-quality development. We must continuously enhance our ability to achieve outstanding results in our respective positions, adopting a spirit of relentless effort, a pioneering drive, and a pragmatic work ethic—unifying our hearts and minds, bolstering our confidence, and striving with determination—to make new and greater contributions to accelerating the enterprise’s transformation and upgrading, achieving a city-wide economic aggregate exceeding one trillion yuan, and realizing a breakthrough first in the biopharmaceutical industry!

Keywords:

Taizhou City leader Zhang Xiaobing visited and conducted a research tour at Boshi Medical Devices Group.

Deng Xiaomei, Vice Chairperson of the Shijiazhuang Municipal Committee of the Chinese People's Political Consultative Conference, visited and conducted a research tour at Shijiazhuang No. 4 Pharmaceutical Group.

Taizhou City leader Zhang Xiaobing visited and conducted a research tour at Boshi Medical Devices Group.